CAMP4 Therapeutics (NASDAQ:CAMP) Director Andrew Schwab Sells 45,147 Shares

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 45,147 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $4.76, for a total transaction of $214,899.72. Following the completion of the sale, the director directly owned 2,579,998 shares in the company, valued at approximately $12,280,790.48. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

CAMP4 Therapeutics Trading Up 0.4%

Shares of CAMP opened at $4.48 on Friday. The firm has a market capitalization of $281.12 million, a price-to-earnings ratio of -1.93 and a beta of 0.22. The firm’s fifty day simple moving average is $4.12 and its 200-day simple moving average is $4.34. CAMP4 Therapeutics Corporation has a twelve month low of $1.41 and a twelve month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. On average, analysts predict that CAMP4 Therapeutics Corporation will post -0.59 earnings per share for the current fiscal year.

Institutional Trading of CAMP4 Therapeutics

A number of large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new stake in CAMP4 Therapeutics in the 4th quarter valued at approximately $61,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at approximately $70,000. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $86,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $115,000. Finally, Goldman Sachs Group Inc. acquired a new position in CAMP4 Therapeutics during the fourth quarter worth $115,000.

Analyst Ratings Changes

CAMP has been the topic of several recent analyst reports. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Piper Sandler reiterated an “overweight” rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.56.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.